Biosante Plans Trial for Prostate Cancer Vaccine
From Associated Press (June 6, 2011)
LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals Inc. said Monday that the Food and Drug Administration has lifted a clinical hold on its potential prostate cancer vaccine, and planning is under way for a mid-stage clinical trial.
The Lincolnshire, Ill., company acquired the potential treatment, labeled GVAX Prostate, when it bought Cell Genesys Inc. in 2009. BioSante said clinical trials of the drug were stopped in 2008, and the FDA's hold on it was a procedural matter tied to that.
GVAX Prostate aims to increase the strength of a patient's immune system in response to cancer, according to a company spokesman.
A drug using a similar method, called Provenge, is already made by Dendreon Corp.
BioSante shares rose 3 cents to $3.03 in late morning trading.
Posted: June 2011